SCHEMBL513581

SCHEMBL513581

CSCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2627770 0.71
Dibromomethane SCHEMBL9837907 0.71
SCHEMBL2498768 0.67
SCHEMBL6842982 0.60
SCHEMBL570237 0.59
SCHEMBL8499440 0.59
SCHEMBL1187 0.59
SCHEMBL862384 0.59
SCHEMBL9426563 0.56
SCHEMBL242448 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023210623-A1 HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME 株式会社エス・ディー・エス バイオテック 2023-11-02 WO disclosed
US-9556187-B2 Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-01-31 US disclosed
EP-3112370-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS Nissan Chemical Industries, Ltd. (JP) 2017-01-04 EP disclosed
EP-2245009-B1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES NOVARTIS AG (CH) 2016-08-10 EP disclosed
US-9403766-B2 Intermediates for producing NEP inhibitors or prodrugs thereof NOVARTIS AG (CH) 2016-08-02 US disclosed
US-20160102102-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-04-14 US disclosed
EP-2508504-B1 PROCESS FOR PREPARATION OF CYCLOALKANEDICARBOXYLIC ACID MONOESTERS SUMITOMO CHEMICAL CO (JP) 2016-04-13 EP disclosed
US-20160060217-A1 Processes HOOK DAVID (CH) 2016-03-03 US disclosed
US-9227934-B2 Processes for producing NEP inhibitors or prodrugs thereof NOVARTIS AG (CH) 2016-01-05 US disclosed
US-20150246881-A1 Processes NOVARTIS AG (CH) 2015-09-03 US disclosed
WO-2009090251-A2 NEW PROCESSES NOVARTIS AG (CH) 2009-07-23 WO disclosed
US-20090030039-A1 Piperidine Derivatives as Cxcr3 Receptor Antagonists JANSSEN PHARMACEUTICA, N.V. (BE) 2009-01-29 US disclosed
EP-1984349-A1 PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2008-10-29 EP disclosed
WO-2007090826-A1 PIPERIDINE DERIVATIVES AS CXCR3 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-16 WO disclosed
US-20030055297-A1 An alkyl, cycloalkyl, arylalkyl dihydroxy compound useful as intermediates; a cost-effective preparation ABBOTT LABORATORIES 2003-03-20 US disclosed
WO-2002081441-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRROLIDINE NEURAMINIDASE INHIBITORS ABBOTT LABORATORIES (US) 2002-10-17 WO disclosed
US-6022822-A Organotin compound and catalyst for transesterification comprising the same RYOJI NOYORI (JP) 2000-02-08 US disclosed
US-5973216-A Method for producing bromomethylcyclopropane KURARAY CO., LTD. (JP) 1999-10-26 US disclosed
US-4061632-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1977-12-06 US disclosed
US-4000277-A 3,11-Dihydro- 6H-pyrazolo[1,5-a]pyrazolo[4',3':5,6]pyrido[4,3-d]pyrimidin-6-one and derivatives thereof E. R. SQUIBB & SONS, INC. (US) 1976-12-28 US disclosed